Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)

About Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals logoTetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TTPH
  • CUSIP: N/A
  • Web: www.tphase.com
  • Market Cap: $318.57 million
  • Outstanding Shares: 51,053,000
Average Prices:
  • 50 Day Moving Avg: $6.89
  • 200 Day Moving Avg: $7.14
  • 52 Week Range: $3.11 - $9.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.04
  • P/E Growth: -0.01
Sales & Book Value:
  • Annual Revenue: $5.01 million
  • Price / Sales: 63.59
  • Book Value: $2.67 per share
  • Price / Book: 2.34
  • EBITDA: ($104,990,000.00)
  • Net Margins: -2,092.20%
  • Return on Equity: -79.79%
  • Return on Assets: -71.63%
  • Current Ratio: 6.12%
  • Quick Ratio: 6.12%
  • Average Volume: 1.30 million shs.
  • Beta: 2.57
  • Short Ratio: 0.89

Frequently Asked Questions for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.76) by $0.07. The company had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company's revenue was up 28.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.47) earnings per share. View Tetraphase Pharmaceuticals' Earnings History.

When will Tetraphase Pharmaceuticals make its next earnings announcement?

Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Tetraphase Pharmaceuticals.

Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2017?

6 brokers have issued twelve-month price targets for Tetraphase Pharmaceuticals' shares. Their forecasts range from $4.00 to $24.00. On average, they expect Tetraphase Pharmaceuticals' share price to reach $14.00 in the next twelve months. View Analyst Ratings for Tetraphase Pharmaceuticals.

Are investors shorting Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals saw a decrease in short interest in September. As of September 15th, there was short interest totalling 2,645,906 shares, a decrease of 32.0% from the August 31st total of 3,889,264 shares. Based on an average trading volume of 920,846 shares, the short-interest ratio is currently 2.9 days. Currently, 5.2% of the shares of the company are short sold.

Who are some of Tetraphase Pharmaceuticals' key competitors?

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the folowing people:

  • Leonard Patrick Gage Ph.D., Chairman of the Board of Directors
  • Guy Macdonald, President and Chief Executive Officer, Director
  • Christopher Watt, Principal Financial Officer, Principal Accounting Officer, Senior Vice President - Finance
  • Maria D. Stahl, Senior Vice President, General Counsel
  • Patrick T. Horn M.D. Ph.D., Chief Medical Officer
  • Jeffrey A. Chodakewitz M.D., Director
  • Geraldine A. Henwood Ph.D., Director
  • Garen G. Bohlin, Independent Director
  • John G. Freund M.D., Independent Director
  • Nancy J. Wysenski, Independent Director

How do I buy Tetraphase Pharmaceuticals stock?

Shares of Tetraphase Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tetraphase Pharmaceuticals' stock price today?

One share of Tetraphase Pharmaceuticals stock can currently be purchased for approximately $6.24.

MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  386
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Tetraphase Pharmaceuticals (NASDAQ:TTPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $14.00 (124.36% upside)
Consensus Price Target History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Price Target History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/4/2017BMO Capital MarketsBoost Price TargetOutperform$13.00 -> $24.00N/AView Rating Details
9/17/2017Needham & Company LLCReiterated RatingHoldHighView Rating Details
9/12/2017Stifel NicolausReiterated RatingBuy$13.00LowView Rating Details
8/28/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$14.00HighView Rating Details
7/11/2017HC WainwrightInitiated CoverageBuy -> Buy$15.00HighView Rating Details
11/4/2016WedbushReiterated RatingNeutral$4.00N/AView Rating Details
5/16/2016GabelliReiterated RatingNeutralN/AView Rating Details
11/19/2015SunTrust Banks, Inc.UpgradeNeutral -> Buy$12.00 -> $21.00N/AView Rating Details
(Data available from 10/24/2015 forward)


Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Earnings by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Earnings History by Quarter for Tetraphase Pharmaceuticals (NASDAQ TTPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.63)N/AView Earnings Details
8/2/2017Q2 2017($0.76)($0.83)$1.54 million$1.59 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.60)($0.79)$1.46 million$1.48 millionViewN/AView Earnings Details
3/8/2017Q4($0.60)($0.61)$1.28 million$1.09 millionViewListenView Earnings Details
11/3/2016($0.50)($0.58)$1.58 million$0.90 millionViewN/AView Earnings Details
8/4/2016Q2($0.46)($0.47)$2.05 million$1.20 millionViewN/AView Earnings Details
5/4/2016Q1($0.44)($0.46)$2.20 million$2.00 millionViewN/AView Earnings Details
2/23/2016Q4($0.44)($0.50)$3.23 million$2.47 millionViewListenView Earnings Details
11/2/2015Q315($0.65)($0.49)$3.20 million$2.90 millionViewN/AView Earnings Details
8/5/2015Q215($0.62)($0.72)$2.73 million$3.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.64)($0.66)$2.90 million$3.00 millionViewN/AView Earnings Details
3/5/2015($0.54)($0.69)$2.74 million$3.07 millionViewN/AView Earnings Details
11/10/2014Q314($0.56)($0.55)$2.86 million$2.29 millionViewN/AView Earnings Details
8/12/2014Q214($0.54)($0.71)$2.79 million$1.30 millionViewN/AView Earnings Details
5/12/2014Q114($0.45)($0.53)$2.97 million$2.50 millionViewN/AView Earnings Details
3/6/2014($0.46)($0.49)ViewN/AView Earnings Details
11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView Earnings Details
5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
2017 EPS Consensus Estimate: ($2.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.62)($0.56)($0.59)
Q2 20172($0.63)($0.58)($0.61)
Q3 20172($0.76)($0.59)($0.68)
Q4 20172($0.61)($0.53)($0.57)
(Data provided by Zacks Investment Research)


Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 41.73%
Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2017Jacques DumasInsiderSell17,500$6.00$105,000.00View SEC Filing  
8/17/2017Jacques DumasInsiderSell7,155$5.86$41,928.30View SEC Filing  
3/15/2017L Patrick GageDirectorBuy11,000$7.49$82,390.00View SEC Filing  
9/1/2015Guy MacdonaldinsiderSell10,000$41.57$415,700.00View SEC Filing  
8/14/2015David Charles LubnerCFOSell9,500$42.92$407,740.00View SEC Filing  
8/13/2015Patrick Taylor HornInsiderSell10,000$44.69$446,900.00View SEC Filing  
8/12/2015L Patrick GageDirectorSell15,000$45.00$675,000.00View SEC Filing  
7/20/2015Guy MacdonaldInsiderSell15,000$50.72$760,800.00View SEC Filing  
7/14/2015David Charles LubnerCFOSell7,500$48.92$366,900.00View SEC Filing  
7/13/2015Patrick Taylor HornInsiderSell10,000$48.93$489,300.00View SEC Filing  
7/6/2015John Craig ThompsonCOOSell10,000$47.91$479,100.00View SEC Filing  
7/1/2015Guy MacdonaldInsiderSell10,000$47.92$479,200.00View SEC Filing  
6/15/2015David Charles LubnerCFOSell17,500$41.45$725,375.00View SEC Filing  
6/15/2015John Craig ThompsonCOOSell10,000$41.51$415,100.00View SEC Filing  
6/8/2015John Craig ThompsonCOOSell22,499$43.26$973,306.74View SEC Filing  
6/1/2015Guy MacdonaldInsiderSell16,087$41.89$673,884.43View SEC Filing  
5/11/2015Guy MacdonaldInsiderSell20,000$41.51$830,200.00View SEC Filing  
1/20/2015Guy MacdonaldInsiderSell34,135$36.59$1,248,999.65View SEC Filing  
10/2/2014John Gordon FreundDirectorSell247,734$20.88$5,172,685.92View SEC Filing  
10/1/2014John Gordon FreundDirectorSell142,146$20.84$2,962,322.64View SEC Filing  
9/30/2014John Gordon FreundDirectorSell152,266$20.18$3,072,727.88View SEC Filing  
9/29/2014John Gordon FreundDirectorSell95,648$20.19$1,931,133.12View SEC Filing  
9/23/2014Guy MacdonaldInsiderSell10,000$18.47$184,700.00View SEC Filing  
9/17/2014Guy MacdonaldInsiderSell10,000$18.00$180,000.00View SEC Filing  
9/17/2014John Gordon FreundDirectorSell144,356$17.21$2,484,366.76View SEC Filing  
9/12/2014John Gordon FreundDirectorSell55,644$17.01$946,504.44View SEC Filing  
9/8/2014John Gordon FreundDirectorSell16,700$15.01$250,667.00View SEC Filing  
9/4/2014John Gordon FreundDirectorSell183,300$15.05$2,758,665.00View SEC Filing  
9/3/2014John Gordon FreundDirectorSell142,100$15.04$2,137,184.00View SEC Filing  
8/20/2014Guy MacdonaldInsiderSell10,000$11.59$115,900.00View SEC Filing  
7/18/2014Guy MacdonaldInsiderSell15,000$10.61$159,150.00View SEC Filing  
6/23/2014John Gordon FreundDirectorSell47,184$13.77$649,723.68View SEC Filing  
6/20/2014John Gordon FreundDirectorSell152,816$13.39$2,046,206.24View SEC Filing  
6/17/2014David Charles LubnerCFOSell13,530$12.51$169,260.30View SEC Filing  
6/17/2014Guy MacdonaldInsiderSell15,000$12.28$184,200.00View SEC Filing  
5/19/2014Guy MacdonaldInsiderSell15,000$9.00$135,000.00View SEC Filing  
5/19/2014Steven Ph.D. GullansDirectorBuy25,000$9.24$231,000.00View SEC Filing  
5/14/2014L Patrick GageDirectorBuy5,000$9.25$46,250.00View SEC Filing  
4/14/2014Guy MacdonaldInsiderSell15,000$9.69$145,350.00View SEC Filing  
3/20/2014Joyce SutcliffeSVPSell11,494$12.41$142,640.54View SEC Filing  
3/6/2014David Charles LubnerCFOSell4,510$13.65$61,561.50View SEC Filing  
2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.00View SEC Filing  
2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.52View SEC Filing  
2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16View SEC Filing  
2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.42View SEC Filing  
9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View SEC Filing  
9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View SEC Filing  
3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View SEC Filing  
3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View SEC Filing  
3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Latest Headlines for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Loading headlines, please wait.



Tetraphase Pharmaceuticals (TTPH) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.